Mike Biotechnology (300463) has agreed to sell its 51% stake in subsidiary Shandong Mike Biotechnology to industry veteran Han Siguang for 17.4129 million yuan, exiting the loss-making unit while retaining regional market access. Han brings 20+ years of medical device distribution expertise in Shandong, aligning with Mike’s strategy to shift from direct ownership to asset-light regional partnerships.
Shandong Mike reported 2023 revenue of 243 million yuan (-11.04M net loss) and 2024 revenue of 227 million yuan (-1.91M net loss), prompting the divestment. Post-sale, Mike will establish a Shandong office to oversee distributor networks, ensuring continued market presence without operational burdens.
The transaction reflects Mike’s focus on profitability over scale, with minimal impact on core operations. Investors should monitor Han’s turnaround plans for the subsidiary.
Related topics：
